drugset / Trial / NCT00661700

A Double-blind "Preferred" Vardenafil Dose Study of QoL and Functional Outcomes in Males With Erectile Dysfunction

NCT00661700

Phase 3 Completed 611 enrolled Bayer
RandomizedParallel-groupDouble-blindTreatment

Summary

To find out more information on how treating impotence with vardenafil in comparison to placebo affects the quality of life (QoL) of men and their partners. Subjects will receive 10mg vardenafil or placebo for 4 weeks followed by an 8 week period when the dose of vardenafil may be reduced to 5mg or increased to 20mg. Subjects will then receive their 'preferred' dose for 14 weeks. During this time Quality of Life Measures will be collected via questionnaires

Timeline

Start
2003-04
Primary completion
2004-05
Completion
2004-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Vardenafil Small molecule 5 mg
Subject Vardenafil Small molecule 10 mg
Subject Vardenafil Small molecule 20 mg

Indications